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INTRODUCTION
Patient blood management (PBM) is the timely application of
evidence-informed medical and surgical concepts designed to
maintain haemoglobin concentration, optimise haemostasis and
minimise blood loss in an effort to improve patient outcomes.
The aim of this consensus statement is to provide recommenda-
tions on the management of anaemia and haematinic deficien-
cies in pregnancy and in the post-partum period as part of PBM
in obstetrics. Amultidisciplinary panel of physicians with exper-
tise in obstetrics, anaesthesia, haematology, policymaking and
epidemiology was convened by the Network for the Advance-
ment of Patient Blood Management, Haemostasis and Throm-
bosis (NATA) in collaboration with the International Federation
of Gynaecology and Obstetrics (FIGO) and the European Board
andCollege of Obstetrics andGynaecology (EBCOG).Members
A multidisciplinary consensus statement developed by the Network for
the Advancement of Patient Blood Management, Haemostasis and
Thrombosis (NATA) in collaboration with the International Federation
of Gynaecology and Obstetrics (FIGO) and the European Board and
College of Obstetrics and Gynaecology (EBCOG).
Correspondence: Prof. Manuel Muñoz, MD, PhD, Department of
Surgical Specialties, Biochemistry and Immunology, School of
Medicine, University of Málaga, Campus de Teatinos s/n, 29071
Málaga, Spain. Tel.: +34 952 131 540; fax: +34 952 131534; e-mail:
mmunoz@uma.es
of the task force assessed the quantity, quality and consistency
of the published evidence and formulated recommendations
using the systemdeveloped by theGrading of Recommendations
Assessment, Development, and Evaluation (GRADE) working
group. The recommendations in this consensus statement are
intended for use by clinical practitioners managing the perinatal
care of women in all settings and by policymakers in charge of
decisionmaking for the update of clinical practice in health-care
establishments. They need to be tailored for application in indi-
vidual patients or any population after consideration of the val-
ues and preferences of both health-care providers and patients,
as well as equity issues; explicit assessment of harms and benefits
of each recommendation; feasibility including resources, capac-
ity and equipment; and implementability.
SUMMARY OF RECOMMENDATIONS
Anaemia in pregnancy
Detection and classification
1. We recommend that a full blood count (FBC) be obtained
to screen for anaemia at booking and at 28weeks, as well as
at any time during pregnancy if symptoms of anaemia are
present (1A).
2. In a woman with microcytic or normocytic anaemia, iron
deficiency (ID) should be confirmed by a trial of oral iron
(unless she is known to have a haemoglobinopathy) or a
serum ferritin measurement (1B).
© 2017 The Authors.
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3. In the absence of an haemoglobin (Hb) increment in
response to a trial of oral iron conducted correctly, we rec-
ommend the further evaluation of iron status by checking
serum ferritin and considering whether additional labora-
tory testing is needed (1C).
4. In anaemic women of Mediterranean, Middle and Far East
and African origin, we recommend confirming the pres-
ence or absence of a haemoglobinopathy either by selective
(based on a family of origin questionnaire) or universal
screening for haemoglobinopathies depending on regional
demographics (1C).
5. Anaemicwomenwith a knownhaemoglobinopathy should
have their serum ferritin checked and should only be
offered oral iron therapy if their serum ferritin level is
<30 ngmL−1 (1B).
Prevention
6. In areas with a high prevalence of anaemia in pregnancy,
we recommend daily oral iron (30–60mg) and folic acid
(400𝜇g) supplementation as part of routine antenatal care
to reduce the risk of maternal anaemia and ID and infant
low birthweight (1B).
7. In areas with a low prevalence of anaemia in pregnancy,
non-anaemic women identified to be at an increased risk of
ID should have their serum ferritin checked early in preg-
nancy and be offered oral supplements (30–60mg/day) if
serum ferritin is <30 ngmL−1 (1C).
Treatment: oral iron
8. We recommend treating mild to moderate iron-deficiency
anaemia (IDA) (Hb≥80 g L−1) in early pregnancy (first and
second trimesters) with oral ferrous iron (80–100mg/day
elemental iron) and folic acid (400𝜇g/day) (1B).
9. Once the Hb concentration is in the normal range, we
recommend that iron supplementation be continued for at
least 3months to replenish iron stores (1A).
Treatment: IV iron
10. We recommend that the administration of intravenous
(IV) iron be considered in women with severe IDA (Hb
<80 g L−1) or newly diagnosed IDA beyond 34weeks of
gestation (1B).
11. We recommend that the administration of IV iron be con-
sidered in women with confirmed IDA who fail to respond
to the correct administration of oral iron (Hb concentra-
tion increase <10 or 20 g L−1 in 2 or 4 weeks, respectively)
or are intolerant to oral iron treatment, if the gestational
age is >14weeks (1B).
Treatment: ESA
12. We suggest that administration of an erythropoiesis-
stimulating agents (ESA) be considered in women with
moderate to severe anaemia not responding to IV iron
due to inappropriate synthesis of, and/or response to,
endogenous erythropoietin levels, in consultation with a
haematologist (2C)
Treatment: RBC transfusion
13. We recommend that referral to a secondary care clinic be
considered if there are significant symptoms of anaemia
and/or severe anaemia (Hb <70 g L−1) or late gestation
(>34weeks) (1C).
14. We recommend that obstetric units have guidelines for red
blood cell (RBC) transfusion in women with antenatal and
post-natal anaemia who are not actively bleeding (1C).
15. In the absence of bleeding, should transfusion be
deemed necessary, we recommend a single-unit
transfusion followed by clinical reassessment and/or
Hb measurement to determine the need for further
transfusion (1C).
Post-partum anaemia
Detection and classification
16. We recommend that pregnant women, especially those
with antenatal anaemia, have an Hb determination prior
to delivery (1C).
17. We recommend that the Hb concentration be determined
in all women after significant peri-partum bleeding (1C).
Prevention
18. We recommend that every effort be made to correct
anaemia prior to delivery (1A).
19. We recommend that women with moderate to severe
anaemia or at high risk of haemorrhage be advised to
deliver in a hospital setting (1C).
20. We recommend active management of the third stage of
labour to minimise blood losses (1A).
21. We recommend cell salvage for women undergoing Cae-
sarean section in whom excessive blood losses are antici-
pated (1C).
22. We recommend that a clear multidisciplinary, multimodal
protocol for management of major obstetric haemorrhage
be in place. This protocol should be activated as soon as
major obstetric haemorrhage is identified (1C).
Treatment: oral iron
23. Oral iron supplementation, either alone or in combi-
nation with folic acid, is recommended for 6–12weeks
following delivery to reduce the risk of anaemia in
settings where gestational anaemia is a public health
concern (1B).
24. We recommend that 80–100mg elemental iron daily
for 3months be given to women with mild to moderate
post-partum anaemia (PPA) (Hb 90–110 g L−1) who are
haemodynamically stable and asymptomatic or mildly
symptomatic (1B).
Transfusion Medicine, 2017 © 2017 The Authors.
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Treatment: IV iron
25. We recommend that women who fail to respond to the
correct administration of oral iron (Hb increase <10 or
20 g L−1 in 2 or 4weeks, respectively) or are intolerant to
oral iron be switched to IV iron (1B).
26. We recommend the administration of IV iron to cover
individually calculated total ID in women with moderate
to severe PPA (Hb <90 g L−1) (1B).
Treatment: ESA
27. In severely anaemic patients with blunted erythropoiesis
due to infection and/or inflammation who do not respond
adequately to IV iron treatment, as well as in severely
anaemic patientswho refuse blood transfusions, we suggest
considering treatment with an ESA after consultation with
the haematologist (2B).
Treatment: RBC transfusion
28. We recommend that all pregnant women should by typed
for blood groups (ABO and D) and screened for the pres-
ence of red cell antibodies early in pregnancy (at book-
ing) and at 28weeks gestation. In D-negative women, the
28-week sample should be taken before the administra-
tion of routine antenatal anti-D Ig prophylaxis (1B) (White
et al., 2016).
29. We recommend that RBC transfusion not be dictated by
Hb levels alone (1C).
30. We recommend that transfusion be considered in
non-bleeding patients with an Hb <60 g L−1, taking
clinical signs and symptoms (risk of bleeding, cardiac
compromise or symptoms requiring immediate attention)
into consideration (1A).
31. In the absence of bleeding, should transfusion be deemed
necessary, we recommend a single-unit transfusion fol-
lowed by clinical reassessment and/or Hb measurement to
determine the need for further transfusion (1C).
PATIENT BLOOD MANAGEMENT
PBM has become the buzzword in transfusion medicine. A
few years ago, clinicians who spoke about PBM at meetings
were considered abstruse visionaries. With time, their vision has
evolved and come into focus. This has allowed the health-care
community to better understand the concept and, most impor-
tantly, to apply it in everyday clinical practice.
Definition of PBM
PBM or, more precisely, patient-centred blood management
“is the timely application of evidence-informed medical and
surgical concepts designed to maintain haemoglobin concen-
tration, optimise haemostasis and minimise blood loss in an
effort to improve patient outcomes” (Shander et al., 2016). By
definition, the approach is multidisciplinary and focuses on
the treatment of each individual patient in whom significant
blood losses are likely to occur and where transfusion of blood
products is part of the established treatment (Gombotz, 2012).
PBM involves – but is not restricted to – the appropriate use
of blood products, defined by the World Health Organisation
(WHO) as “the transfusion of safe blood products to treat
a condition leading to significant morbidity or mortality that
cannot be prevented or managed effectively by other means.”
(WHO, 2001a).
Although PBM is known best in the management of elective
surgical procedures, it can (and should) also be applied to any
procedure likely to result in excessive bleeding, post-procedural
anaemia and the use of blood products. The “three pillars” of
PBM require that (i) perioperative erythropoiesis be optimised,
(ii) blood losses be minimised and (iii) tolerance to anaemia be
harnessed appropriately (Isbister, 2013). PBM is a continuous
process, initiated early in the preoperative period and continued
intra- and post-operatively.The whole concept of PBM has been
elegantly summarised by Hofmann et al. (Hofmann et al., 2007)
(Figure S1, Supporting Information).
Importance of PBM
At present, preoperative anaemia is often ignored, surgery pro-
ceeds as planned, and RBCs are transfused when deemed neces-
sary (Muñoz et al., 2015; Meier et al., 2016) Yet, cohort studies
(in cardiac, non-cardiac and vascular surgery) have shown that
preoperative anaemia is associated with an increased incidence
of post-operative adverse events, including mortality (Wu et al.,
2007; Ranucci et al., 2012; Gupta et al., 2013) In addition, preop-
erative anaemia and low intraoperative haemoglobin (Hb) con-
centration are important predictors of perioperative allogeneic
RBC transfusions (Muñoz et al., 2015).
Blood transfusions entail a number of known risks (e.g.
transmission of infectious agents, transfusion reactions,
ABO mismatch, transfusion-related acute lung injury,
transfusion-associated circulatory overload, etc.) and other
less well-known ones. The latter are related, in essence, to
emergent pathogens and to immunomodulation (increased
incidence of infections and cancer recurrence) (Goodnough
& Shander, 2012). At present, it remains difficult to deter-
mine whether the observed adverse events and mortality are
related to preoperative anaemia per se or to the increase in
allogeneic transfusions secondary to anaemia (Figure S2).
Notwithstanding, the overall outcome is negative, so preoper-
ative anaemia must be managed in a timely fashion (Muñoz
et al., 2015). PBM implementation remains inadequate, even in
centres where audits are conducted on a regular basis (Gom-
botz et al., 2014; Van der Linden & Hardy, 2016). That being
said, it has not been unequivocally demonstrated that cor-
rection of preoperative anaemia is associated with improved
outcomes (Muñoz et al., 2015). High-quality evidence in
that direction would definitely improve adherence to PBM
principles.
© 2017 The Authors. Transfusion Medicine, 2017
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CONSENSUS ORGANISATION
Scope and purpose
This consensus statement reflects the position of the NATA, the
FIGO and the EBCOG. It includes recommendations on the
management of anaemia and haematinic deficiencies in preg-
nancy and in the post-partum period as part of PBM in obstet-
rics.The prevention and treatment of post-partum haemorrhage
(PPH) will be addressed in a separate consensus statement.
Target audience
The recommendations in this consensus statement are intended
for use by clinical practitioners managing perinatal care of
women in all settings and by policymakers in charge of decision
making for the update of clinical practice in health-care estab-
lishments. It is important to note that these recommendations
need to be tailored for application in individual patients or any
population after consideration of the values and preferences of
both health-care providers and patients, as well as equity issues;
explicit assessment of harms and benefits of each recommenda-
tion; feasibility including resources, capacity and equipment; and
implementability. Further involvement of relevant stakeholders
at the local level is advised.
Development process
Amultidisciplinary panel of physicians with expertise in obstet-
rics, anaesthesia, haematology, policymaking and epidemiology
was convened in Paris, France on 28 February 2015 by NATA
in collaboration with FIGO and EBCOG with the aim of devel-
oping a consensus statement on the detection, evaluation and
management of anaemia and haematinic deficiencies in preg-
nancy and in the post-partum period. The experts were asked
to:
1. Determine the scope of the problem;
2. Identify the optimal methods to detect the problem and
establish a differential diagnosis;
3. Assess the evidence and its quality for the detection, eval-
uation and management of anaemia and haematinic defi-
ciencies in pregnancy and in the post-partum period;
4. Agree on recommendedmethods tominimise peri-partum
blood losses;
5. Define the role of RBC transfusions in pregnancy and in
the post-partum period and
6. Issue recommendations on the use of oral iron, IV iron
and ESA to treat anaemia during pregnancy and in the
post-partum period.
Members of the task force assessed the quantity, quality
and consistency of the published evidence and formulated
recommendations using the system developed by the GRADE
working group (Guyatt et al., 2008) (Figure S3). A preliminary
version of the consensus statement was drafted by M. M. and
circulated among the members of the panel for additional input
and editing. The document was further reviewed by two experts
in the field (F. G. and N. M.) who were not previously involved
in the process. The document was then submitted for publica-
tion and underwent the journal’s regular peer-review process.
The recommendations in this statement are expected to remain
valid for an estimated standard period of 10 years.
Plans for dissemination, adaptation and evaluation
This statement will be disseminated to all members of NATA,
FIGO and EBCOG, and open access will be provided. Addi-
tionally, the recommendations will be presented at international
forums and specialised events targeting clinicians in charge of
themanagement of anaemia andhaematinic deficiencies in preg-
nant and post-partum women.
ANAEMIA IN PREGNANCY
Anaemia occurs frequently during pregnancy. Anaemia can
be aggravated by childbirth and is associated with adverse
events. In most cases, it is possible to identify and correct
the situation prior to childbirth, thereby improving patient
outcomes.
Definitions
During pregnancy, there is a considerable increase (40–45%) in
plasma volume (Sanghavi & Rutherford, 2014). The maternal
plasma erythropoietin level also increases during pregnancy,
with a peak in the third trimester, to accelerate erythropoiesis
and help compensate for the dilution effect. These changes,
resulting in an increase in total blood volume, are important to
meet the increased demands of blood flow for the uterus and
foetus, and may protect pregnant woman against the adverse
effects of blood loss during labour. However, the disproportion
in volume expansion between the plasma and RBC volumes
results in haemodilution, and therefore, cut-off values for the
definition of anaemia during pregnancy should be lower than
those for non-pregnant women (Milman, 2008).
The definition of a normal Hb concentration in pregnancy is
controversial and lacks consistency across studies. Ideally, the
cut-off values for pre-partum anaemia should be derived from
studies of healthy iron-replete (as well as folate- and vitamin
B12-replete) women who had a normal singleton pregnancy and
delivery (Milman et al., 2000; Milman et al., 2007). The WHO
has defined anaemia in pregnancy as an Hb <110 g L−1 and
classified anaemia as mild (Hb 100–109 g L−1), moderate (Hb
70–99 g L−1) or severe (Hb <70 g L−1) (WHO, 2011). There
are no WHO recommendations on the use of different Hb
cut-off points by trimester, but it is recognised that during the
second trimester of pregnancy, Hb concentration decreases by
approximately 5 g L−1. Additionally, the WHO states that ‘mild’
anaemia is a misnomer as iron deficiency is already advanced by
the time anaemia is detected. Iron deficiency has consequences
even when no anaemia is clinically apparent. The American
Transfusion Medicine, 2017 © 2017 The Authors.
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College of Obstetricians and Gynaecologists (ACOG) and
British Committee for Standards in Haematology (BCSH)
guidelines define anaemia in pregnancy as an Hb <110 g L−1
in the first trimester and <105 g L−1 in the second and third
trimesters (ACOG, 2008; Pavord et al., 2012).
Prevalence
It is estimated that in 2011, 38% of pregnant women worldwide
were anaemic, with wide variations between regions (Stevens
et al., 2013). The prevalence of anaemia among pregnant
women was 48.7% in the Southeast Asian region, compared
with 46.3% in the African region and 25.8% in the European
region.
Causes
ID accounts for most cases of anaemia in pregnant women
(Stevens et al., 2013) as iron stores are often insufficient to
meet the increasing demands of pregnancy due to the increase
in RBC mass (450mg), foetal growth (225mg), placental
development (80mg) and blood losses during normal vaginal
delivery (250mg). A total of approximately 1000mg of extra
iron is required during a normal pregnancy, equivalent to
6.3mg day−1. In addition, lactation will require an additional
supply of 1mg day−1 (Bothwell, 2000). Without supplementa-
tion, 80% of women at term will have no detectable iron stores
according to bone marrow samples, and it will take 2 years of
normal dietary iron to replace the iron lost with each pregnancy
(De Leeuw et al., 1966).
Althoughmost of the burden of anaemia is assumed to be due
to ID, other contributors should be considered. Nutritional defi-
ciencies of folate and vitamin B12, infectious diseases, parasitic
infections and haemoglobinopathies are additional and often
neglected causes of anaemia (WHO, 2001c; Kassebaum et al.,
2014).
Consequences
Iron depletion reduces iron availability for erythropoiesis and
results in decreased Hb and oxygen delivery to tissues, resulting
in clinical signs and symptoms. These include reduced exercise
tolerance, tiredness and fatigue, impaired cognitive performance
tests, decreased mental concentration ability, irritability, ten-
dency of depression, palpitations, headaches, pallor, glossitis,
angular cheilitis, nail ridging, koilonychias, reduced immunity,
increased frequency of infections and pica. Anaemia is the most
common indirect cause of adversematernal outcomes, including
maternal mortality (Filippi et al., 2016). Low Hb concentrations
indicative ofmoderate or severe anaemia during pregnancy have
been associated with an increased risk of premature delivery and
child mortality and infectious diseases (Filippi et al., 2016). An
Hb <70 g L−1 is an associated cause in up to half of the mater-
nalmortalities worldwide.Moreover, IDAmay affect growth and
development both of the foetus in utero and of the newborn child
in the long term (Lumbiganon et al., 2014; Vogel et al., 2014;
New &Wirth, 2015) (Table S1).
There are significant concerns about the suboptimal manage-
ment of maternal anaemia even in high-resource areas, likely
due in part to a lack of consistent good-quality evidence man-
dating therapeutic interventions (Parker et al., 2012).The devel-
opment of more standardised approaches to reporting outcomes
of maternal anaemia, together with the impact of therapy, is a
research priority (Allard, 2015).
Detection and classification
TheNational Institute for Health and Care Excellence (NICE) in
the UK recommends that screening for haematological condi-
tions in pregnancy should be offered at booking and at 28weeks,
thus allowing adequate time for treatment should anaemia be
detected (NICE, 2008). Hb concentrations below the normal
range for pregnancy should be investigated and iron supplemen-
tation considered if indicated. It has been proposed that the first
antenatal haematological screening should also include serum
ferritin, thus allowing the early assessment of body iron status
and an immediate decision whether or not there is an indication
for oral iron supplementation in early pregnancy (Milman,
2006). However, there is currently no consensus on this issue.
The 2015U.S. Preventive Services Task Force recommendation
concludes that the current evidence is insufficient to assess the
balance of benefits and harms of screening for IDA in pregnant
women to prevent adverse maternal health and birth outcomes
(Siu, 2015). The authors indicate, however, that this recommen-
dation does not apply to pregnant women who are malnour-
ished, have symptoms of IDA or have special haematological
conditions or nutritional needs that increase iron requirements.
In the UK, unselected screening with routine use of serum
ferritin is generally not recommended, although guidelines note
that it may be helpful in individual centres with a particularly
high prevalence of women at risk of ID (Pavord et al., 2012).
A FBC screening test to detect anaemia in pregnancy may
reveal an Hb below the defined threshold. Following detection
of anaemia, a standard haematological approach is generally
applied to determine if the anaemia is secondary to increased
blood loss or decreased production of red cells. Red cell indices,
other FBC parameters and a blood film are usually reviewed.
Blood film reviews may identify variation in size and shape
of cells, uniformity, fragments, inclusion bodies or sickle cells.
However, they are time consuming and are hardly ever per-
formed at diagnosis. The mean red cell volume (MCV) may
suggest a microcytic (ID, haemoglobinopathy), macrocytic
(vitamin B12 or folate deficiency, thyroid disease, reticulocytosis,
increased alcohol intake or liver dysfunction) or normocytic
(anaemia of chronic disease, marrow suppression or dual
haematinic deficiency) cause for anaemia. Additional blood
tests may be considered, including haematinics (iron, vitamin
B12, folate), and in certain cases, reticulocytes, haemoglobin
electrophoresis, lactate dehydrogenase, haptoglobin, bilirubin
and a direct antiglobulin test (to exclude haemolysis) would be
© 2017 The Authors. Transfusion Medicine, 2017
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needed for a definite classification of anaemia (Hallberg et al.,
1993; van den Broek et al., 1998; Muñoz et al., 2011).
In the presence of IDA during pregnancy, the MCV, the
mean red cell haemoglobin (MCH) and the mean red cell
haemoglobin concentration (MCHC) may be low, and the
blood film may confirm microcytic, hypochromic red cells
and elliptocytes. However, the increased erythropoietic drive
in pregnancy leads to a higher proportion of young, large, red
cells and may mask the effect of ID on MCV. A normal MCV
does not exclude ID, whereas microcytic, hypochromic indices
may occur in haemoglobinopathies. The red cell distribution
width, i.e. the variation in the volumes of red cells, can help
differentiate ID from other microcytic anaemias, for instance,
thalassaemia. Therefore, it is important to confirm whether a
haemoglobinopathy is present. Plasma or serum ferritin is a
measure of iron stores. It declines early in the development of ID
and is not affected by ingestion of iron. Because serum ferritin
is an acute-phase protein, it is recommended to determine the
C-reactive protein level at the same time if inflammation is
present or suspected. In pregnancy, a serum ferritin concen-
tration<30 ngmL−1 indicates insufficient body iron reserves
and hence a high risk for developing IDA; a serum ferritin
concentration<12 ngmL−1 indicates established ID at all stages
of pregnancy (Hallberg et al., 1993; van den Broek et al., 1998;
Muñoz et al., 2011).
A trial of oral ferrous iron therapy (100mg elemental
iron/day) has also been considered a first-line diagnostic test
for IDA (ACOG, 2008; Pavord et al., 2012). In women of
Mediterranean, Middle and Far East and Africa descent who
may have haemoglobinopathies, an oral iron trial could be
offered whilst waiting for their haemoglobinopathy status to be
determined. The chances of iron overload would be minimal,
and the benefits would outweigh the risks. An Hb increment
in 2–4weeks (positive response) is supportive of a diagnosis
of IDA. In case of negative response, further investigation
including serum vitamin B12 and folate should be considered
(Annex S1).
Recommendations
• Recommendation 1: We recommend that an FBC be
obtained to screen for anaemia at booking and at 28weeks
as well as at any time during pregnancy if symptoms of
anaemia are present (1A).
• Recommendation 2: In a woman with microcytic or nor-
mocytic anaemia, ID should be confirmed by a trial of oral
iron (unless she is known to have a haemoglobinopathy) or
a serum ferritin measurement (1B).
• Recommendation 3: In the absence of an Hb increment in
response to a trial of oral iron conducted correctly, we rec-
ommend the further evaluation of iron status by checking
serum ferritin and considering whether additional labora-
tory testing is needed (1C).
• Recommendation 4: In anaemic women ofMediterranean,
Middle and Far East and African origin, we recommend
confirming the presence or absence of a haemoglobinopa-
thy either by selective (based on a family of origin ques-
tionnaire) or universal screening for haemoglobinopathies
depending on regional demographics (1C).
• Recommendation 5: Anaemic women with a known
haemoglobinopathy should have their serum ferritin
checked and should only be offered oral iron therapy if
their serum ferritin level is <30 ngmL−1 (1B).
Good practice points
• Aside from the oral iron trial, the serum ferritin level is the
most useful and easily available laboratory parameter for
assessing ID during pregnancy.
• Serum ferritin levels <12 ngmL−1 indicate established
ID. A serum ferritin level< 30 ngmL−1, with or with-
out anaemia, indicates insufficient body iron reserves
and should prompt treatment. However, as ferritin is an
acute-phase reactant, a serum ferritin level within the
normal range may not rule out ID in the presence of
inflammation.
Prevention
Interventions aimed at preventing ID and IDA in pregnancy
include iron- and folic acid-containing supplements, fortifica-
tion of staple foods with iron and other vitamins and minerals,
health and nutrition education, control of parasitic infections
and improvement in sanitation (INACG, 1977). A supplemen-
tal daily dose of 30–60mg of elemental ferrous iron is recom-
mended by the WHO for all pregnant women in all settings
(WHO, 2012). Inmost countries, a prenatal supplement contain-
ing 30mg iron is offered, although iron content may vary (e.g.
45mg in the USA and 60mg in the UNICEF product). A study
of Danish women showed that a supplement of 40mg ferrous
iron/day for 18weeks of gestation appears adequate to prevent
ID in 90% of the women and IDA in at least 95% of the women
during pregnancy and the post-partum period (Milman et al.,
2005). Prophylactic iron supplementation should be started as
soon as pregnancy is confirmed and maintained throughout its
entire duration. In settings where anaemia in pregnant women
is a severe public health problem (prevalence of 40% or higher),
a daily dose of 60mg of elemental ferrous iron is preferred over
a lower dose (WHO, 2012).
Two recent meta-analyses concluded that daily prenatal use
of iron substantially reduces the risk of maternal anaemia and
ID in pregnancy but that the positive effect on other maternal
and infant outcomes is less clear (Haider et al., 2013; Peña-Rosas
et al., 2015a). Implementation of iron supplementation recom-
mendations improves birthweight, probably leading to a reduc-
tion in the risk of low birthweight, but it produces heterogeneous
results depending on the population’s background risk for low
birthweight and anaemia, as well as the level of adherence to the
intervention (Peña-Rosas et al., 2015a).
A Cochrane systematic review suggests that intermittent
iron and folic acid supplementation regimens produce similar
Transfusion Medicine, 2017 © 2017 The Authors.
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maternal and infant outcomes at birth as daily supplementa-
tion and are associated with fewer gastrointestinal side effects
and increased compliance (Peña-Rosas et al., 2015b). The risk
of reaching high Hb in mid and late pregnancy was reduced,
whereas the risk of having mild anaemia near term increased.
Thus, intermittent oral ferrous iron may be a feasible alterna-
tive to daily iron supplementation among those pregnant women
who are not anaemic and have adequate antenatal care.
The 2015U.S. Preventive Services Task Force recommenda-
tion states that the current evidence is insufficient to assess the
balance of benefits and harms of routine iron supplementation
for pregnant women in order to prevent adverse maternal health
and birth outcomes (Siu, 2015). Similarly, routine iron supple-
mentation for all pregnant women has not been recommended
in the UK (Pavord et al., 2012).
As for folic acid, a prophylactic dose of 400𝜇g (0.4mg)
per day, peri-conceptionally and throughout pregnancy, is
recommended for the prevention of neural tube defects. If
supplementation is started after the first trimester of pregnancy,
it will not help prevent congenital anomalies. Therefore, folic
acid supplementation should begin as early as possible (ideally
prior to conception).
Daily oral iron and folic acid supplementation during preg-
nancy is a strong WHO recommendation, with overwhelming
implications for patients, clinicians, policymakers, quality mon-
itors and funding agencies (WHO, 2012).There are currently no
specific recommendations for prophylactic vitamin B12 supple-
mentation in pregnancy.
Recommendations
• Recommendation 6: In areas with a high prevalence of
anaemia in pregnancy, we recommend daily oral iron
(30–60mg) and folic acid (400𝜇g) supplementation as
part of routine antenatal care to reduce the risks of mater-
nal anaemia and ID and infant low birthweight (1B).
• Recommendation 7: In areas with a low prevalence of
anaemia in pregnancy, non-anaemic women identified to
be at increased risk of ID should have their serum ferritin
checked early in pregnancy and be offered oral supple-
ments (30–60mg day−1) if serum ferritin is <30 ngmL−1
(1C).
Good practice points
• According to the United Nations International Multiple
Micronutrient Preparation, in high-risk areas, supple-
ments may be formulated to include, in addition to iron
and folic acid, other vitamins and minerals to overcome
other possible maternal micronutrient deficiencies.
• In malaria-endemic areas, provision of iron and folic acid
supplements should be implemented in conjunction with
measures to prevent, diagnose and treat malaria (WHO,
2012). In cases where a combined folic acid–iron tablet is
not available, a daily dose of 400𝜇g folic acid can be used
separately (RBMP, 2015).
• Non-anaemic women at risk of ID include those with
previous anaemia, multiparity, consecutive pregnancy
<1 year following delivery and vegetarians. Special atten-
tion should also be given to pregnant teenagers, women at
high risk of bleeding or with a recent history of bleeding,
and Jehovah’s Witnesses (Pavord et al., 2012). When logis-
tically difficult, these women should receive daily oral iron
(30–60mg) without checking serum ferritin.
• All pregnant women should be counselled and receive
plain-language written information regarding diet and
iron-rich food sources, factors that may inhibit or promote
iron absorption and the importance of maintaining ade-
quate iron stores during pregnancy (Pavord et al., 2012).
Treatment: Oral iron
The primary treatment for mild to moderate cases of IDA (Hb
70–105 g L−1) during the first and second trimesters is daily oral
iron therapy, and doses ranging from 40 to 200mg day−1 of ele-
mental ferrous iron, ideally on an empty stomach, have been
recommended. The same also applies to depleted iron stores
without anaemia (serum ferritin <30 ngmL−1) at the beginning
of pregnancy (60mg day−1 elemental iron) because of the addi-
tional requirement for iron during the course of the pregnancy
(ACOG, 2008; Breymann et al., 2011; Pavord et al., 2012; WHO,
2012).
However, lower-dosage iron supplements can be effective for
the treatment of IDA and are associated with less gastrointestinal
side effects. In non-anaemic young women with plasma ferritin
levels <20 ngmL−1, providing lower dosages (40–60mg iron)
and avoiding twice-daily dosing was found to maximise frac-
tional absorption due to the effect of absorbed iron on hepcidin
release (Moretti et al., 2015). Whether these data also apply to
anaemic women is not known. As anaemia-induced hypoxia and
erythropoietin production down-regulate the expression of hep-
cidin, this may counterbalance the stimulatory effect of iron,
allowing the use of higher oral iron doses (Muñoz et al., 2011).
Recommendations
• Recommendation8:Werecommend treatingmild tomod-
erate IDA (Hb≥80 g L−1) in early pregnancy (first and sec-
ond trimesters) with oral ferrous iron (80–100mg day−1
elemental iron) and folic acid (400𝜇g day−1) (1B).
• Recommendation 9: Once the Hb concentration is in the
normal range, we recommend that iron supplementation
be continued for at least 3months to replenish iron stores
(1A).
Good practice points
• Women should be advised on the appropriate intake of oral
iron to optimise absorption (empty stomach, preferably 1 h
before breakfast, with a vitamin C-containing drink).
• Systems must be in place for rapid review and follow up of
blood results.
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• Clinical staff should be familiar with the iron content
of over-the-counter supplements that women take during
pregnancy as many contain insufficient elemental iron to
be therapeutic.
Treatment: Intravenous iron
A switch to an IV iron preparation can be advantageous in
certain cases, including: (i) a lack of response to oral iron (Hb
levels rising by less than 10 or 20 g L−1 within 14 or 28 days,
respectively) due to impaired intestinal absorption; (ii) lack
of compliance or intolerance of oral iron preparations (gas-
trointestinal side effects); (iii) severe, advanced or progressive
anaemia (Hb <80 g L−1); and (iv) desire for rapid anaemia
treatment (e.g. advanced gestational age, Jehovah’s Witness
faith) (Breymann et al., 2011; WHO, 2011; WHO, 2012) (for a
summary of the characteristics of available IV iron formulations,
Table S2).
We identified 12 randomised controlled trials (RCT) com-
paring oral and IV iron in a total of 1519 pregnant women
(14–37weeks of gestation) with anaemia (Hb 69–109 g L−1)
(al-Momen et al., 1996; Singh et al., 1998; Bayoumeu et al., 2002;
Al et al., 2005; Khalafallah et al., 2010; Neeru et al., 2012; Shafi
et al., 2012; Froessler et al., 2013; Kochhar et al., 2013; Abhi-
lashini et al., 2014; Gupta et al., 2014; Breymann et al., 2017)
(Table S3). Compared with oral iron, antenatal IV iron admin-
istration hastened recovery from anaemia, led to a higher rate
of anaemia correction and resulted in better replenishment of
iron stores and lower rates of adverse drug events or poor treat-
ment compliance. No study showed superiority of oral iron over
IV iron.
One study assessed the long-term effect of iron therapy dur-
ing pregnancy on well-being and health-related quality of life
(HRQoL) during a 3-year follow-up period (Khalafallah et al.,
2012). Patients receiving IV iron had significantly higher Hb
and serum ferritin levels (P< 0.001). There were strong asso-
ciations between iron status and a number of HRQoL items,
including improved general health, improved physical energy,
less psychological downheartedness, less clinical depression and
overall improved mental health. The duration of breastfeed-
ing was longer in women who had received IV iron. In a
more recent trial, in which a significantly larger proportion
of women treated with IV iron vs oral iron achieved correc-
tion of anaemia (Hb ≥110 g L−1; 83.5 vs 70.2%; P< 0.05) and
did so within a shorter time frame (3.4 vs 4.3 weeks; P< 0.05),
changes in all SF-36 components favoured IV iron, with signifi-
cant improvements in vitality and social functioning (Breymann
et al., 2017).
The available evidence suggests benefits of IV iron adminis-
tration, especially for patients with moderate to severe anaemia.
Intramuscular iron administration is less effective (Wali et al.,
2002; Singh & Singh, 2013) and no longer recommended in
the majority of clinical situations; however, it may be an option
in certain clinics in case of high throughput or community
administration. Two observational studies found no differences
between different IV iron formulations (Christoph et al., 2012;
Myers et al., 2012). IV iron formulations allowing the adminis-
tration of large doses in a single session may facilitate treatment
and be more convenient both for the patient (fewer venepunc-
tures, less time out fromwork) and for the health system (shorter
administration time, fewer visits to day hospital and fewer ambu-
lance transfers) (Table S2).
Neither serious life-threatening adverse events attributable
to IV iron nor significant differences in maternal or foetal
outcomes were reported in the studies reviewed above.
Nonetheless, these studies commonly used Hb and iron indices
as endpoints and were usually underpowered to evaluate
the impact of IV iron therapy on more clinically relevant
outcomes.
On 27 June 2013, the EuropeanMedicines Agency’s Commit-
tee for Medicinal Products for Human Use (CHMP) completed
a review of IV iron-containing medicines and concluded that
all IV iron preparations carry a small risk of adverse reactions
that can be life-threatening if not treated promptly. “During
pregnancy, the CHMP noted, allergic reactions are of particular
concern as they can put both the mother and unborn child at
risk. IV iron medicines should therefore not be used during
pregnancy unless clearly necessary. Treatment should be con-
fined to the second or third trimester, provided the benefits of
treatment clearly outweigh the risks to the unborn baby (such
as anoxia and fetal distress)” (EMA, 2013). A number of iron
experts disagree with this statement because overemphasising
the avoidance of IV iron may not only be counterproductive
but also potentially harmful (Auerbach et al., 2015). Guidance
for risk minimisation and management of hypersensitivity
reactions to IV iron has been published (Rampton et al., 2014).
If minor infusion reactions occur with one IV iron formulation,
switching to another is appropriate and safe (Auerbach et al.,
2015). Nevertheless, we should be aware of the small risk of
reactions, and as such, it is not appropriate to go straight for
IV iron in all cases. First-line treatment is oral iron based on
safety and cost, and the benefits of IV iron outweigh its risks
when the oral route is insufficient or poorly tolerated, provided
measures are taken to minimise the risk of hypersensitivity
reactions (EMA, 2013). Women should be informed of poten-
tial side effects of IV iron, and written information should be
provided.
Recommendations
• Recommendation 10:We recommend that the administra-
tion of IV iron be considered in women with severe IDA
(Hb <80 g L−1) or newly diagnosed IDA beyond 34weeks
of gestation (1B).
• Recommendation 11:We recommend that the administra-
tion of IV iron be considered in women with confirmed
IDA who fail to respond to correct administration of oral
iron (Hb concentration increase <10 or 20 g L−1 in 2 or 4
weeks, respectively) or are intolerant to oral iron treatment
if the gestational age is >14weeks (1B).
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Good practice points
• IV iron should not be given together with oral iron or in
the presence of an active infection.
• Health-care staff should be trained to detect, evaluate and
manage hypersensitivity reactions in accordance with pub-
lished guidelines.
Treatment: Erythropoiesis-stimulating agents
There is only one each of an RCT, observational study and case
series including a total of 135 women with confirmed IDA (Hb
83–95 g L−1; >16weeks of pregnancy) treated with iron sucrose
or iron sucrose plus an ESA (Breymann et al., 1995; Breymann
et al., 2001; Krafft et al., 2009) (Table S2). Compared with IV
iron alone, addition of an ESA, namely recombinant human
erythropoietin (rHuEPO), resulted in higher Hb increments and
higher rates of anaemia correction, especially if endogenous
erythropoietin levels were low at baseline. Thus, patients not
adequately responding to IV iron treatment might benefit from
the additional administration of ESAs, although the level of
evidence is low.
Neither serious life-threatening adverse events attributable to
ESAs nor significant differences in maternal or foetal outcomes
were reported in the studies reviewed above. However, it must be
remembered that ESAs are not approved for treating anaemia in
pregnant women without chronic kidney disease (off-label use).
Women should be informed of potential side effects, and written
information should be provided.
Recommendation
• Recommendation 12: We suggest that administration of
an ESA be considered in women with moderate to severe
anaemia not responding to IV iron due to inappropriate
synthesis of and/or response to endogenous erythropoietin
levels, in consultation with a haematologist (2C).
Treatment: Red blood cell transfusion
Our literature search identified only one small multicen-
tre RCT (n= 72) examining the effect of prophylactic vs
indication-driven (restrictive) transfusion in pregnant women,
and this study was restricted to women with sickle cell anaemia
(Koshy et al., 1988). No other studies have been identified that
report on the effect of RBC transfusion on maternal or neonatal
mortality, functional or performance status or measures of
foetal outcome in a general maternity population. Therefore,
any recommendations are based on expert consensus regarding
maternal or foetal indications for blood transfusion.
In the context of severe bleeding, there is no question that
blood transfusion can save lives; however, it is less certain
whether blood transfusion is of benefit to maternity patients
not actively bleeding. Furthermore, many inherent risks are
involved with blood transfusion, and certain women may refuse
blood transfusions due to religious beliefs. Therefore, blood
transfusion should be reserved for those at risk of further
bleeding, imminent cardiac compromise or symptoms requiring
immediate attention (maternal indications).
Severe anaemia with a maternal Hb <60 g L−1 has been
associated with abnormal foetal oxygenation, resulting in
non-reassuring foetal heart rate patterns, reduced amniotic
fluid volume, foetal cerebral vasodilatation and foetal mortality
(Sifakis & Pharmakides, 2000; Carles et al., 2003). In such a case,
maternal transfusion should be considered for foetal indications
(ACOG, 2008; NICE, 2008). Transfusion indications should be
backed up by local guidelines and effective patient information
(Pavord et al., 2012).
Recommendations
• Recommendation 13: We recommend that referral to a
secondary care clinic be considered if there are signifi-
cant symptoms of anaemia and/or severe anaemia (Hb
<70 g L−1) or late gestation (>34weeks) (1C).
• Recommendation 14: We recommend that obstetric units
have guidelines for RBC transfusion in women with ante-
natal and post-natal anaemia who are not actively bleeding
(1C).
• Recommendation 15: In the absence of bleeding, should
transfusion be deemed necessary, we recommend a
single-unit transfusion followed by clinical reassessment
and/or Hbmeasurement to determine the need for further
transfusion (1C).
Good practice points
• Women receiving an RBC transfusion should be given full
information regarding the indication for transfusion and
alternatives available, according to national policy proce-
dures (WHO, 2001b).
• Informed consent should be given by the patient and doc-
umented in the clinical notes.
• One red cell concentrate contains approximately 240mg of
iron, which is insufficient to replace total ID and replen-
ish iron reserves.Therefore, concomitant IV iron to replete
the iron reserves in order tominimise the number of trans-
fusions may be considered. Concomitant ESA may also
be considered to maximise erythropoiesis and minimise
transfusions.
POST-PARTUM ANAEMIA
Anaemia as well as ID without anaemia are common in the
post-partum period and represent significant health problems
in women of reproductive age. Predisposing factors should be
identified and modified when possible, and routine screening
should be considered in order to provide early and appropriate
treatment.
Definition
Ideally, the cut-off value for PPA should be derived from the
studies of healthy iron-replete women who had a normal
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singleton pregnancy and delivery without excessive blood
losses (<500mL). However, PPA is usually defined by an Hb
<100 g L−1 within 24–48 h after delivery, although a recom-
mendation has been made to define PPA as an Hb <110 g L−1
at 1 week post-partum and Hb <120 g L−1 at 8 weeks, the latter
corresponding to the definition of anaemia in non-pregnant
women of reproductive age proposed by the WHO (Milman,
2011; WHO, 2011; Milman, 2012).
Prevalence
PPA is common. In a consecutive series of German women
(n= 43 807) who delivered in 1993–2008, the prevalence of PPA
(Hb< 100 g L−1) 24–48 h after delivery was 22% (up to 50% if
PPA was defined as Hb <110 g L−1) (Bergmann et al., 2010). In
Danish healthy women, the prevalence of PPA 1week after nor-
mal delivery was 14% with iron supplementation and 24% with-
out iron supplementation (Milman et al., 1991). In developing
countries, the prevalence of PPA is in the range of 50–80% and
represents a major cause of maternal morbidity and mortality. It
has been estimated that peri-partum haemorrhage and anaemia
are responsible for approximately 100 000 delivery-associated
maternal mortalities yearly on a global scale.
Causes
In some countries, pre-partum IDA and/or acute bleeding
during delivery are the main causes of PPA (Patel et al., 2006;
Bergmann et al., 2010; Allary et al., 2013). Normal peri-partum
blood losses range from 200 to 300mL, whereas PPH is
defined as blood losses ≥500mL and severe PPH as blood
losses ≥1000mL (RCOG, 2009; Rajan & Wing, 2010). In a
fraction of women, factors such as ethnicity, multiple birth,
folate and vitamin B12 deficiencies, inflammatory response
(especially after Caesarean section), infectious disorders and
haemoglobinopathies may contribute to PPA (Krafft et al., 2003;
Milman, 2008; Murray-Kolb & Beard, 2009; Bergmann et al.,
2010).
Consequences
In the post-partum period, anaemia as well as ID without
anaemia are associated with decreased physical performance
(tiredness, breathlessness, palpitations), increased risk of infec-
tion (urinary tract), impaired lactation, reduced cognitive
abilities, emotional instability and depression and thus repre-
sent significant health problems in women of reproductive age
(Bergmann et al., 2010). They also interfere with mother–child
interactions as women experience difficulties in caring for their
newborn, which compromises the emotional bonds between
the mother and baby (Perez et al., 2005). Maternal iron supple-
mentation protects against these negative effects (Murray-Kolb
& Beard, 2009). PPA may also increase health-care resource
utilisation and costs (Duarte et al., 2014). Therefore, factors
predisposing to PPA should be identified and modified when
possible.
Detection and classification
Routine screening for PPA should be considered in order to pro-
vide early and appropriate treatment. According to UK guide-
lines, every woman should have an Hb determination after sig-
nificant peri-partum bleeding (Pavord et al., 2012). Due to the
combination of peri-partum haemorrhage and haemodynamic
changes, the post-partum Hb concentration should be allowed
to stabilise after delivery for at least 48 h before a reliable diagno-
sis of PPA can bemade. Hb concentration at 1week post-partum
allows a more reliable detection of PPA (Milman, 2012). In case
of excessive blood loss (>1000mL), a protocol should be in place
to manage the haemorrhage (including sequential Hb measure-
ments) (Pavord et al., 2012).
As is the case with antenatal anaemia, an algorithm for
the diagnosis of PPA should be implemented. Some guidelines
state that no treatment is required if the Hb concentration is
>110 g L−1.
Recommendations
• Recommendation 16: We recommend that pregnant
women, especially those with antenatal anaemia, have an
Hb determination prior to delivery (1C).
• Recommendation 17: We recommend that the Hb con-
centration be determined in all women after significant
peri-partum bleeding (1C).
Good practice point
• A complete blood count plus a serum ferritin level at
4–8weeks post-partumare adequate to assess anaemia and
iron status and diagnose ID/IDA in the majority of women
with antenatal anaemia or significant peri-partumbleeding
(Milman, 2008).
Prevention
As pre-partum ID and IDA are closely associated with the occur-
rence of PPA, securing an adequate iron status during pregnancy
is the first step in the prevention of PPA; anaemic women are
more at risk of bleeding and more vulnerable to even moder-
ate amounts of blood loss. All placebo-controlled studies have
shown that pregnant women taking oral iron supplements have
an improved iron status and a lower rate of anaemia both dur-
ing pregnancy and in the post-partum period compared with
women taking placebo (Haider et al., 2013; Peña-Rosas et al.,
2015a; Peña-Rosas et al., 2015b).
Many medical and gynaecological/obstetrical disorders pre-
dispose to peri-partum bleeding, PPH and PPA. Uterine atony is
the most common aetiology for post-partum bleeding. Risk fac-
tors for uterine atony include prolonged second stage of labour,
operative vaginal delivery, over-distention of the uterus (e.g.
foetal macrosomia, multiple gestation, polyhydramnios), medi-
cations (e.g. nifedipine,magnesium sulphate, halogenated anaes-
thetic agents), abnormal placentation and retained conception
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products. Traumatic lacerations of the uterus or vagina and con-
genital or acquired coagulation disorders, including anticoag-
ulant therapy, can also cause excessive blood loss at delivery
(Myers, Myers et al., 2012). Therefore, careful obstetric evalua-
tion and treatment prior to and during delivery is essential to
reduce the frequency of both expected and unexpected compli-
cations and bleeding (Milman, 2012).
Different approaches may be used to prevent PPH, depend-
ing on the setting and availability of skilled birth attendants and
resources, and international guidelines on PPH vary in their rec-
ommendations (Bohlmann & Rath, 2014). Active management
of the third stage of labour and post-partum care immediately
following placenta removal, regardless of third-stage manage-
ment (active vs expectant), reduces blood losses and transfu-
sion requirements.The usual components of active management
of the third stage of labour include: administration of oxytocin
(alternatively, ergometrine or misoprostol) within 1min after
birth of the infant, cord clamping and controlled cord traction
and uterine massage after delivery of the placenta (Prendiville
et al., 2000; Lalonde and International Federation of Gynecology
and Obstetrics, 2012). Cell salvage is recommended for women
undergoing caesarean section in whom blood loss >500mL is
anticipated, provided that health-care teams have the necessary
expertise and experience and the patient’s informed consent is
obtained (RCOG, 2009). Recent publications suggest that adher-
ing to local guidelines significantly reduces the prevalence of
severe PPH (Bohlmann & Rath, 2014).
Even with major advances in the prevention of PPH, some
womenwill still require treatment for excessive bleeding. Timely
interventions and appropriate access or referral and transfer to
basic or comprehensive emergency obstetric care facilities for
treatment are essential to save the woman’s life (Lalonde and
International Federation of Gynecology and Obstetrics, 2012).
Therefore, a protocol for PPH management should be in place
(RCOG, 2009; Rajan & Wing, 2010; Lalonde and International
Federation of Gynecology and Obstetrics, 2012; Pavord et al.,
2012). It is beyond the scope of this document to go into details
regarding the prevention and management of PPH, which will
be the topic of a separate consensus statement.
Recommendations
• Recommendation 18: We recommend that every effort
be made to correct moderate to severe anaemia prior to
delivery (1A).
• Recommendation 19: We recommend that women with
anaemia or at high risk of haemorrhage be advised to
deliver in a hospital setting (1C).
• Recommendation 20:We recommend active management
of the third stage of labour to minimise blood losses (1A).
• Recommendation 21: We recommend cell salvage for
women undergoing caesarean section in whom excessive
blood losses are anticipated (1C).
• Recommendation 22: We recommend that a clear mul-
tidisciplinary, multimodal protocol for management of
major obstetric haemorrhage be in place. This protocol
should be activated as soon asmajor obstetric haemorrhage
is identified (1C).
Treatment: Oral iron
In women with mild to moderate anaemia who are haemo-
dynamically stable, asymptomatic or mildly symptomatic,
treatment should be initiated with oral ferrous iron (80–100mg
elemental iron daily for at least 3months) (WHO, 2016). The
interaction between food intake and absorption of iron supple-
ments should be taken into account and clearly explained to
the patient in order to increase the efficacy and reduce the side
effects of the treatment (Pavord et al., 2012).
In the three studies comparing oral iron with place-
bos, anaemia symptoms were not reported, and it remains
unknown whether benefits of oral iron outweigh documented
gastrointestinal harms (Markova et al., 2015). In addition,
implementation of oral iron therapy is inconsistent. In 2008, a
multicentre study across 11maternity units in theUK (n= 2013)
found that 30% of women who had post-natal Hb levels checked
were anaemic, and depending on the centre, 16–86% of these
women received iron therapy (Barroso et al., 2011). These data
suggest that ensuring more effective iron replenishment during
the hospital stay could alleviate the burden of anaemia in the
post-partum period.
Recommendations
• Recommendation 23: Oral iron supplementation, either
alone or in combination with folic acid, is recommended
for 6–12weeks following delivery to reduce the risk of
anaemia in settings where gestational anaemia is a public
health concern (1B).
• Recommendation 24:We recommend that 80–100mg ele-
mental iron daily for 3months be administered to women
with mild to moderate PPA (Hb 90–110 g L−1) who are
haemodynamically stable, asymptomatic or mildly symp-
tomatic (1B).
Good practice points
• Whenever possible, Hb concentration in women receiving
oral iron for PPA should be determined after approximately
2–4weeks in order to evaluate the efficacy of the treatment.
• The interaction between food intake and absorption of
ferrous and ferric iron supplements should be taken into
account and clearly explained to the patient.
Treatment: Intravenous iron
Women with confirmed IDA and lack of response (Hb incre-
ment <10 or 20 g L−1 in 2 or 4weeks, respectively) or intoler-
ance to oral iron may benefit from IV iron. We identified 14
RCTs comparing oral and IV iron in a total of 2363 women with
PPA who were followed up for 2–12weeks (Breymann et al.,
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2000; Bhandal & Russell, 2006; VanWyck et al., 2007; Breymann
et al., 2008; Seid et al., 2008; Westad et al., 2008; Giannoulis
et al., 2009; Daniilidis et al., 2011; Verma et al., 2011; Froessler
et al., 2013; Jain et al., 2013; Perelló et al., 2014; (Holm et al.,
2017); Rathod et al., 2015) (Table S4). Compared with oral iron
(standard therapy), IV iron resulted in faster Hb increments
during treatment, higher final Hb increments, higher rates of
anaemia correction, higher ferritin increments and lower rates
of drug-related adverse events. There were no significant differ-
ences in treatment compliance or transfusion rates, and no RCT
showed superiority of oral iron over IV iron.
Regarding quality of life, in one RCT, the total fatigue score
was significantly improved in the IV iron group at weeks 4,
8 and 12 compared with the oral iron group, whereas SF-36
scores did not differ (Van Wyck et al., 2007). In another study,
a 1200-mg single-dose infusion of IV iron was associated with
a statistically significant aggregated change of approximately
1 point on the 16-point Multidimensional Fatigue Inventory,
suggesting less fatigue within 12weeks after PPH (Holm et al.,
2017). In contrast, an RCT found that patients assigned to IV
iron or oral iron experienced similar increases in SF-36 scores
and decreases in Fatigue Linear Analog Scale Assessment scores,
and between-group differences were not significant at any study
interval (Bhandal & Russell, 2006).
There were one RCT and one observational study compar-
ing iron sucrose with ferric carboxymaltose in women with PPA
(Pfenniger et al., 2012; Rathod et al., 2015). Mean post-partum
Hb ranged between 77 and 82 g L−1.The RCT showed that, com-
pared with iron sucrose, ferric carboxymaltose administration
produced greater andmore rapid increases of Hb and serum fer-
ritin as well as a higher rate of anaemia correction at the end
of follow up (the same was true for both IV iron preparations
compared with oral iron) (Rathod et al., 2015). In the obser-
vational study, no difference in efficacy was observed between
iron sucrose and ferric carboxymaltose (Pfenniger et al., 2012).
Overall, there were no differences in transfusion exposure or
drug-related adverse events in these studies. As stated above,
IV iron formulations allowing the administration of single high
doses aremore convenient both for the patient and for the health
system.
No serious, life-threatening adverse events or increases in
post-partum infection rates attributable to IV ironwere reported
in the studies reviewed above. IV iron was superior to oral iron
regarding gastrointestinal harms; however, anaphylaxis occurred
in three women and cardiac events occurred in two women
(more data are needed to establish whether this was caused by
IV iron) (Markova et al., 2015). This is in agreement with the
EuropeanMedicines Agency’s CHMP report concluding that the
benefits of IV iron exceed its risks provided adequate measures
are taken to minimise the risk of allergic reactions (EMA, 2013).
All staff involved in IV iron administration should be aware of
recommendations on the prevention and management of rare
hypersensitivity reactions (Rampton et al., 2014).
Transient decreases in serum phosphate are frequent among
patients receiving IV ferric carboxymaltose but also among those
receiving oral iron (Bhandal & Russell, 2006; Van Wyck et al.,
2007; Breymann et al., 2008). Hypophosphataemia was asymp-
tomatic and was not associated with reports of mortalities,
adverse events or treatment discontinuation in this setting.
Breymann et al. did not observe a transfer of iron sucrose
into maternal milk in women receiving a 100-mg dose during
an observation period of 4 days (Breymann et al., 2007). How-
ever, mean iron values in breast milk increased transitorily after
ferric carboxymaltose administration (mean dose, 1350mg)
(Breymann et al., 2008) or iron isomaltoside 1000 (1200mg)
(Holm et al., 2017) when compared to control, although no dif-
ferences in breastfed infant outcomes were observed.
Currently available information suggests IV iron adminis-
tration is beneficial, especially for patients with moderate to
severe anaemia. However, a recent Cochrane review suggests
that RCTs with clinical endpoints are needed (Markova et al.,
2015). Women should be informed about the potential side
effects of IV iron therapy, and written information should be
provided.
Recommendations
• Recommendation 25: We recommend that women with
confirmed ID who fail to respond to the correct admin-
istration of oral iron (Hb increase <10 or 20 g L−1 in 2
or 4weeks, respectively) or are intolerant to oral iron be
switched to IV iron (1B).
• Recommendation 26: We recommend the administration
of IV iron to cover individually calculated total ID in
women with moderate to severe PPA (Hb <90 g L−1) (1B).
Good practice points
• IV iron should not be given together with oral iron or in
the presence of an active infection.
• Staff should be trained to detect, evaluate and manage
hypersensitivity reactions in accordance with published
guidelines.
Treatment: Erythropoiesis-stimulating agents
Women with a higher post-partum inflammatory response (e.g.
after caesarean section) may show a poor response to iron
therapy, an inadequate erythropoietin secretion for the level of
anaemia and/or blunted response to endogenous erythropoietin,
as seen in anaemia of chronic diseases (Weiss & Goodnough,
2005). These women, as well as those severely anaemic refusing
blood transfusion, may benefit from adjuvant therapy with an
ESA, but the quality of the evidence is moderate to low.
There are two RCTs including a total 114 women with
moderate to severe PPA who received oral iron sulphate
(80–200mg day−1) or oral iron sulphate plus ESA (rHuEPO
40 000–180 000 IU) and were followed up for 6weeks (Huch
et al., 1992; Makrydimas et al., 1998). Compared with oral iron
alone, rHuEPO plus oral iron resulted in faster Hb increments
during treatment, higher Hb increments at 6 weeks, similar rates
Transfusion Medicine, 2017 © 2017 The Authors.
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of drug-related adverse events and no significant differences in
transfusion rates, which were very low (Table S4).
There are five RCTs including a total of 272 womenwithmod-
erate to severe PPAwho received iron sucrose (300–1600mg) or
iron sucrose plus ESA (rHuEPO20 000–40 000 IU) andwere fol-
lowed up for between 2 and 6weeks (Lebrecht et al., 1995; Brey-
mann et al., 1996; Breymann et al., 2000; Wågström et al., 2007;
Krafft & Breymann, 2011). Most women also received oral iron
(80–160mg day−1) after discharge. Compared to IV iron alone,
rHuEPO plus IV iron resulted in a trend to faster Hb increment
during treatment, similar Hb and ferritin increments at the end
of the study period, similar rates of drug-related adverse events
and no significant differences in transfusion rates, which were
very low. The benefit seemed to be greatest in the blunted ery-
thropoiesis subgroupwith elevatedC-reactive protein levels after
caesarean section (Breymann et al., 1996; Krafft & Breymann,
2011) (Table S3).
No serious, life-threatening adverse events attributable to ESA
therapy were reported in the studies reviewed above. However,
it must be remembered that in pregnant women without chronic
kidney disease, administration of ESAs is off label. Women
should be informed of potential side effects, and written infor-
mation should be provided.
Recommendation
• Recommendation 27: In severely anaemic patients with
blunted erythropoiesis due to infection and/or inflamma-
tion andnot responding adequately to IV iron treatment, as
well as in severely anaemic patientswho refuse blood trans-
fusion, we suggest considering treatment with an ESA after
consultation with the haematologist (2B).
Treatment: Red blood cell transfusion
The 2009–2012 MBRRACCE-UK Perinatal Mortality Surveil-
lance Report identified 17 direct mortalities due to obstetric
haemorrhage (Knight et al., 2014). Three of these women were
anaemic antenatally. The report included a review of how care
could have been improved and suggested actions including fol-
low up of abnormal blood results and treatment of antenatal
anaemia. The decision to prescribe RBC transfusion is mainly
based on post-partum Hb concentration: RBC transfusion may
be recommended when the Hb concentration is <60 g L−1,
whereas it is rarely appropriate in women with an Hb concen-
tration >90 g L−1.
In a series of 1954 Finnish women with moderate PPA (Hb
70–100 g L−1), 13.3% received 1–2 RBC units (Palo et al., 2007).
RBC transfusions resulted in higher Hb levels on discharge but
had no impact on length of hospital stay. Thus, in the absence
of risk of bleeding, cardiac compromise or symptoms requiring
immediate attention, transfusion is unlikely to be appropriate
when the Hb is 70–90 g L−1.
In a recent non-inferiority trial, 521 women with acute
anaemia (estimated blood loss >1000mL, Hb 48–79 g L−1,
12–24 h post-partum) who did not have severe symptoms
of anaemia or severe comorbidities were randomised to
non-intervention (iron and folic acid supplementation; RBC
transfusion permitted in case of severe symptoms of anaemia)
or RBC transfusion (target Hb ≥89 g L−1) (Prick et al., 2014a,
2014b). Overall, 517 RBC units were transfused in the inter-
vention arm vs 88 in the non-intervention arm. Adverse events
and Hb concentration at 6weeks were comparable. Although
non-inferiority could not be demonstrated, there was only a
small difference in physical fatigue at 3 and 7 days post-partum
and no differences in secondary outcomes. Additionally, a
cost-effectiveness analysis showed that RBC transfusion was,
on average, €249 more expensive than non-intervention (Prick
et al., 2014a, 2014b).
Although the implementation of a restrictive approach
seems clinically justified, RBC transfusions were needed in 33
(12.6%) women in the non-intervention group (Prick et al.,
2014a, 2014b). Using data from 262 randomised and 362
non-randomised women, the authors derived a model where
clinical variables (primiparity, multiple pregnancy, total blood
loss during delivery >1500mL and Hb concentration 12–24 h
post-partum) and HRQoL were independent predictors for the
need of RBC transfusion (Prick et al., 2015). This model may be
an important tool for patient counselling and decision making
in clinical practice.
In summary, RBC transfusion should be restricted to severely
anaemic women who develop circulatory instability due to PPH,
should be given in the minimal amount required to stabilise the
patient and should be followed by pharmacological treatment of
anaemia.
Recommendations
• Recommendation 28: We recommend that all pregnant
women should be ABO and D typed and screened for the
presence of red cell antibodies early in pregnancy (at book-
ing) and at 28weeks gestation. In D-negative women, the
28-week sample should be taken before the administra-
tion of routine antenatal anti-D Ig prophylaxis (1B) (White
et al., 2016).
• Recommendation 29: We recommend that RBC transfu-
sion not be dictated by Hb levels alone (1C).
• Recommendation 30: We recommend that transfusion be
considered in non-bleeding patients with anHb<60 g L−1,
taking clinical signs and symptoms (risk of bleeding, car-
diac compromise or symptoms requiring immediate atten-
tion) into consideration (1A).
• Recommendation 31: In the absence of bleeding, should
transfusion be deemed necessary, we recommend a
single-unit transfusion followed by clinical reassessment
and/or Hbmeasurement to determine the need for further
transfusion (1C).
Good practice points
• In post-partum women who refuse RBC transfusions and
are not actively bleeding, there is the option of using a
© 2017 The Authors. Transfusion Medicine, 2017
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plasma expander, IV iron and ESA for the treatment of
anaemia.
• Women receiving RBC transfusion should be given
full information regarding the indication(s) for trans-
fusion and alternatives available. Consent should be
given by the patient and documented in the clinical
notes.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1.The three pillars of patient blood management.
Figure S2. The relationship between anaemia, transfusion and
adverse events.
Figure S3.The grading system used to evaluate the quality of the
evidence and grade recommendations.
Table S1. Complications/adverse effects of anaemia during
pregnancy.
Table S2. Some characteristics of the different intravenous iron
formulations.
Table S3. Clinical studies of intravenous iron intravenous iron
and/or erythropoiesis-stimulating agents for the treatment of
iron-deficiency anaemia in pregnancy.
Table S4. Clinical studies of intravenous iron and/or
erythropoiesis-stimulating agents for the treatment of
iron-deficiency anaemia in the postpartum period.
Annex S1. Diagnosis of vitamin B12 and folic acid deficiency.
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